Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Grows By 9,129.5%

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 774,911 shares, an increase of 9,129.5% from the January 15th total of 8,396 shares. Approximately 30.5% of the company’s stock are sold short. Based on an average daily volume of 9,185,858 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 9,185,858 shares, the days-to-cover ratio is currently 0.1 days. Approximately 30.5% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VivoSim Labs in a report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Hedge Funds Weigh In On VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent SEC filing. 8.23% of the stock is currently owned by institutional investors.

VivoSim Labs Trading Down 1.5%

Shares of NASDAQ:VIVS traded down $0.03 on Tuesday, hitting $1.92. The company had a trading volume of 112,439 shares, compared to its average volume of 3,630,930. The stock has a market cap of $5.01 million, a price-to-earnings ratio of -0.44 and a beta of 1.21. The stock has a 50 day moving average price of $2.08 and a 200 day moving average price of $2.37. VivoSim Labs has a 1-year low of $1.41 and a 1-year high of $21.96.

VivoSim Labs (NASDAQ:VIVS) last announced its earnings results on Thursday, November 6th. The company reported ($0.98) EPS for the quarter. The company had revenue of $0.03 million for the quarter. VivoSim Labs had a negative return on equity of 28.83% and a negative net margin of 1,413.57%.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.